SurfON试验:早产晚期和足月早期呼吸窘迫婴儿早期表面活性物质治疗与期待治疗的多中心开放标签随机对照试验研究方案
SurfON试验为多中心开放标签随机对照试验,计划在45个英国新生儿病房招募1522名34+0至38+6周胎龄、生后24小时内因呼吸窘迫需无创呼吸支持的婴儿,1:1随机分配至早期表面活性物质治疗组或期待治疗组,主要比较新生儿住院时间和严重呼吸衰竭发生率,并评估其他围产结局和成本效益。
要点
- 早产晚期和足月早期婴儿占全部出生很大比例,30-40%需新生儿病房入院,主要因呼吸系统疾病。
- SurfON试验旨在评估早期表面活性物质治疗是否优于期待治疗,主要结局为新生儿住院时间和严重呼吸衰竭发生率。
- 目前针对该人群的管理证据稀少,尚无大型随机对照试验,临床实践存在差异。
核心结论
- SurfON试验旨在评估早产晚期和足月早期呼吸窘迫婴儿中早期表面活性物质治疗与期待治疗相比能否改善结局,主要比较新生儿住院时间和严重呼吸衰竭发生率。
研究设计与样本
- 多中心、开放标签、随机对照试验,涉及45个英国新生儿病房,计划30个月内招募1522名婴儿。
- 纳入标准为胎龄34+0至38+6周、生后24小时内因呼吸窘迫需无创呼吸支持的婴儿,按1:1随机分配至早期表面活性物质治疗组或期待治疗组。
主要发现
- 早产晚期和足月早期婴儿中30-40%需新生儿病房入院,主要因呼吸系统疾病。
- 早期表面活性物质治疗组接受单剂CUROSURF®(天然动物来源表面活性物质),给药时机和剂量将被收集。
- 次要目标评估其他围产结局和成本效益。
关键数值与推荐
- 主要结局为新生儿住院时间和严重呼吸衰竭发生率。
- 纳入胎龄范围为34+0至38+6周,需在生后24小时内因呼吸窘迫接受无创呼吸支持。
- 计划招募1522名婴儿,随机分配比例1:1。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Late preterm and early term infants are a large proportion of all births. Historically, outcomes were thought to be similar to those of full term infants, but recent evidence demonstrates worse outcomes. Although serious morbidity is less common than in very preterm infants, the impact of modest illness in large numbers of more mature neonates is significant, with 30-40% requiring neonatal unit (NNU) admission, primarily for respiratory disease. The SurfON trial aims to evaluate whether early surfactant therapy improves outcomes compared with expectant management in late preterm and early term infants with respiratory distress. The primary objectives are to compare neonatal hospital stay and incidence of severe respiratory failure, with secondary objectives assessing other perinatal outcomes and cost-effectiveness. METHODS: The SurfON trial is a multicentre, open-label, randomised controlled trial involving 45 UK NNUs, aiming to recruit 1522 infants over 30 months. Eligible infants are those born at 34+0 to 38+6 weeks' gestation who require noninvasive respiratory support for respiratory distress within 24 h of birth. Infants are randomised in a 1:1 allocation ratio to either early surfactant therapy or expectant management. Infants randomised to the early surfactant therapy group will receive a single dose of CUROSURF®, a natural animal-derived surfactant. IMP administration reflects local site policy and procedure and may be completed by any clinician for whom this falls within their usual scope of practice, following confirmation of eligibility. The IMP is a commonly used drug in neonates and is being used in line with standard care. Side effects are uncommon and usually transient. Timing and dosage of IMP administration will be collected. Surfactant is a stock drug for all NNUs and will be administered and accounted for as per local practice. DISCUSSION: Evidence-based guidance for the management of late preterm and early term infants is sparse, and no previous large randomised controlled trials have focused on this population. Management of respiratory distress in late preterm and early term infants varies. Some clinicians prefer early surfactant administration to prevent deterioration-78others delay treatment to avoid mechanical ventilation. This inconsistency highlights the need for trials to establish an evidence base. Unexpected neonatal morbidity and prolonged hospitalisation cause significant psychological distress for families, impacting breastfeeding and maternal well-being. High intensive care workload and associated costs pose challenges for the NHS (National Health Service). Evidence-based management could improve outcomes and reduce healthcare burdens. TRIAL REGISTRATION: ISRCTN 15915394. Registered on 20th February 2020 https://www.isrctn.com/ISRCTN15915394 .
引用
- Boyle EM, Bari V, Bradley PJ, et al. SurfON trial: study protocol for a multicentre, open-label, randomised controlled trial of early surfactant therapy versus expectant management in late preterm and early term infants with respiratory distress. Trials. 2025. PMID: 41327430. doi:10.1186/s13063-025-09271-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。